TTPH Tetraphase Pharmaceuticals Inc.

1.19
+0.02  (+2%)
Previous Close 1.17
Open 1.17
Price To Book 0.66
Market Cap 63814603
Shares 53,625,717
Volume 135,031
Short Ratio
Av. Daily Volume 704,456

NewsSee all news

  1. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Tetraphase Pharmaceuticals, Inc. (TTPH) and Encourages TTPH Investors to Contact the Firm
  2. Robbins Arroyo LLP: Shareholders Allege That Tetraphase Pharmaceuticals, Inc. (TTPH) Misled Shareholders
  3. New Research: Key Drivers of Growth for Tetraphase Pharmaceuticals, Olympic Steel, Belden, KAR Auction Services, BWX Technologies, and Sparton — Factors of Influence, Major Initiatives and Sustained Production
  4. Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
  5. Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra — New Horizons, Emerging Trends, and Upcoming Developments

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19572607
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19552459
  3. CT ORDER - Confidential treatment order 181242367
  4. CT ORDER - Confidential treatment order 181171880
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171028

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial to be completed 2Q 2019.
TP-271
Community-acquired bacterial pneumonia (CABP)

Latest News

  1. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Tetraphase Pharmaceuticals, Inc. (TTPH) and Encourages TTPH Investors to Contact the Firm
  2. Robbins Arroyo LLP: Shareholders Allege That Tetraphase Pharmaceuticals, Inc. (TTPH) Misled Shareholders
  3. New Research: Key Drivers of Growth for Tetraphase Pharmaceuticals, Olympic Steel, Belden, KAR Auction Services, BWX Technologies, and Sparton — Factors of Influence, Major Initiatives and Sustained Production
  4. Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
  5. Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra — New Horizons, Emerging Trends, and Upcoming Developments
  6. Edited Transcript of TTPH earnings conference call or presentation 8-Nov-18 9:30pm GMT
  7. Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates
  8. Tetraphase: 3Q Earnings Snapshot
  9. War against the superbugs: Mass. biotechs step up to fight antibiotic resistance
  10. Is Tetraphase Pharmaceuticals Inc’s (NASDAQ:TTPH) Balance Sheet Strong Enough To Weather A Storm?
  11. Options Traders Expect Huge Moves in Tetraphase (TTPH) Stock
  12. DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19572607
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19552459
  3. CT ORDER - Confidential treatment order 181242367
  4. CT ORDER - Confidential treatment order 181171880
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171028
  6. 8-K - Current report 181169783
  7. 8-K - Current report 181160010
  8. 8-K - Current report 181079228
  9. 8-K - Current report 181040307
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988201